Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Ultragenyx Pharmaceutical Inc. (RARE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update Second quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total Crysvita revenue grew 20% versus the second quarter 2022 Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million NOVATO, Calif. – Aug 03, 2023 – Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended June 30, 2023 and provided its financial guidance fo..."
07/28/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
02/10/2022 8-K Quarterly results
Docs: "Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update 2021 total revenue of $351.4 million and 2021 Crysvita® revenue in Ultragenyx territories1 of $192.6 million 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 million Strong Dojolvi® launch continues with approximately 270 patients on reimbursed commercial therapy in the United States as of the end of 2021 Year-end 2021 cash balance of approximately $1.0 billion"
11/02/2021 8-K Quarterly results
Docs: "Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update Third quarter 2021 total revenue of $81.6 million including Crysvita1 revenue to Ultragenyx of $50.3 million 2021 Crysvita revenue in Ultragenyx territories1 now expected towards the upper end of the$180 million to $190 million range previously provided"
08/02/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
10/27/2020 8-K Quarterly results
Docs: "Ultragenyx Reports Third Quarter 2020 Financial Results and Corporate Update Third quarter 2020 total revenue of $81.5 million and Crysvita1 revenue of $37.3 million Increased lower end of Crysvita1 guidance range; updated full year range is $130 million to $140 million Dojolvi launch off to a strong start"
07/30/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
02/13/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "Strong U.S. launch continues, with approximately 170 new patients on reimbursed commercial therapy in the United States in the third quarter 2019. • U.S. Crysvita label expanded. The U.S. FDA approved a label expansion for Crysvita, which now includes clinical data demonstrating superiority of treatment with Crysvita versus conventional therapy in pediatric patients, and improvement in stiffness and maintenance of efficacy in adult patients with longer-term treatment. The indication has also been expanded to include infants as young as six months of age. Crysvita Supplemental Biologics License Application for Tumor-Induced Osteomalacia • Ultragenyx plans to submit a sBLA to the U.S. FDA for Crysvita for the treatment of TIO in the first half of 2020. UX007 NDA for the Treatme..."
08/01/2019 8-K Quarterly results
Docs: "Strong U.S. launch continues, with approximately 960 patients on reimbursed commercial therapy in the United States at the end of the second quarter 2019. UX007 NDA submitted to FDA for the treatment of Long-Chain Fatty Acid Oxidation Disorders • Ultragenyx submitted a New Drug Application to the FDA earlier this week. The FDA previously granted Rare Pediatric Disease Designation and Fast Track designation, which enables eligibility for Priority Review, if relevant criteria are met. The company expects to hear back from FDA on submission acceptance and review designation within 60 days. Clinical-stage Gene Therapy Programs Advance • DTX301 Phase 1/2 study in ornithine transcarbamylase deficiency: Previous data from Cohorts 1 and 2 demonstrated that the two responders maintain..."
05/06/2019 8-K Quarterly results
Docs: "Strong launch continues in the United States, with approximately 730 patients on reimbursed commercial therapy at the end of the first quarter 2019. • Crysvita was approved in Brazil for the treatment of XLH in adults and pediatric patients one year of age and older. Crysvita is approved in three key regions of the world including North America, Europe, and now the first country in Latin America. UX007 in Long-Chain Fatty Acid Oxidation Disorders • Fast Track Designation and Rare Pediatric Disease Designation granted by U.S. Food and Drug Administration . Fast Track designation allows for early and frequent communication with the FDA, and also enables eligibility for Priority Review, if relevant criteria are met. • Ultragenyx is on track to submit a New Drug Applicatio..."
02/19/2019 8-K Quarterly results
05/07/2018 8-K Quarterly results
Docs: "Ultragenyx Reports First Quarter 2018 Financial Results and Corporate Update"
02/20/2018 8-K Quarterly results
Docs: "Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update"
11/02/2017 8-K Quarterly results
Docs: "Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate Update"
07/27/2017 8-K Quarterly results
Docs: "Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update Burosumab US BLA submission planned for August 2017"
05/04/2017 8-K Form 8-K - Current report
02/16/2017 8-K Form 8-K - Current report
11/07/2016 8-K Quarterly results
Docs: "Ultragenyx Reports Third Quarter 2016 Financial Results and Corporate Update"
08/08/2016 8-K Quarterly results
Docs: "Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update"
05/09/2016 8-K Form 8-K - Current report
02/25/2016 8-K Quarterly results
Docs: "Ultragenyx Reports Fourth Quarter 2015 and Full-Year 2015 Financial Results and Corporate Update"
11/09/2015 8-K Quarterly results
Docs: "Ultragenyx Reports Third Quarter 2015 Financial Results and Corporate Update"
08/13/2015 8-K Quarterly results
Docs: "Ultragenyx Reports Second Quarter 2015 Financial Results and Corporate Update"
05/11/2015 8-K Quarterly results
Docs: "Ultragenyx Reports First Quarter 2015 Financial Results and Corporate Update"
03/25/2015 8-K Quarterly results
Docs: "Ultragenyx Reports Fourth Quarter and Full-Year 2014 Financial Results and Corporate Update"
11/10/2014 8-K Quarterly results
Docs: "Ultragenyx Reports Third Quarter 2014 Financial Results and Corporate Update"
08/11/2014 8-K Quarterly results
Docs: "Ultragenyx Reports Second Quarter 2014 Financial Results and Corporate Update"
05/12/2014 8-K Quarterly results
Docs: "Ultragenyx Reports First Quarter 2014 Financial Results and Corporate Update"
03/24/2014 8-K Quarterly results
Docs: "Ultragenyx Reports Fourth Quarter and Full Year 2013 Financial Results"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy